Baseline Albumin-Bilirubin grade as a predictor of response and outcome of regorafenib therapy in patients with hepatocellular carcinoma: a systematic review and meta-analysis

Huilin Xu(Wuhan University), Wei Ge(People's Liberation Army No. 150 Hospital), Nan Zhao(Army Medical University), Dingjie Zhou(Wuhan University), Sanjaya K. Satapathy(Northwell Health), Dedong Cao(Wuhan University), Vishal G. Shelat(National University of Singapore), Xixian Tang, Giuseppe Aprile(Ospedale Santa Maria della Misericordia di Udine), Ximing Xu(Jiangsu University), Anbing He, Hrishikesh Samant(Louisiana State University Health Sciences Center Shreveport), Francisco Tustumi
Annals of Translational Medicine
January 1, 2023
10.21037/atm-23-405
Cited by 0

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet|2023|701
Rechallenge for Patients With <i>RAS</i> and <i>BRAF</i> Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan
|JAMA Oncology|2018|418
Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial
|The Lancet Oncology|2020|333
Entrectinib, a Pan–TRK, ROS1, and ALK Inhibitor with Activity in Multiple Molecularly Defined Cancer Indications
|Molecular Cancer Therapeutics|2016|317